Evidence map›Paper›PMID 40084355›Full record

ArticleAmerican journal of cancer research2025

Patho-Net: enhancing breast cancer classification using deep learning and explainable artificial intelligence.

Kalappanaickenpatty Suriaprakasam Manojee, Athiappan Rajiv Kannan

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kalappanaickenpatty Suriaprakasam ManojeeDepartment of Information Technology, Kongunadu College of Engineering and Technology (Autonomous) Thottiam, Trichy, Tamilnadu, India.
Athiappan Rajiv KannanDepartment of Computer Science and Engineering, K.S.R. College of Engineering (Autonomous) Tiruchengode, Namakkal, Tamilnadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a disorder affecting women globally, and hence an early and precise classification is the best possible treatment to increase the survival rate. However, the breast cancer classification faced difficulties in scalability, fixed-size input images, and overfitting on limited datasets. To tackle these issues, this work proposes a Patho-Net model for breast cancer classification that overcomes the problems of scalability in color normalization, integrates the Gated Recurrent Unit (GRU) network with the U-Net architecture to process images without the need for resizing and computational efficiency, and addresses the overfitting problems. The proposed model collects and normalizes histopathology images using automated reference image selection with the Reinhard method for color standardization. Also, the Enhanced Adaptive Non-Local Means (EANLM) filtering is utilized for noise removal to preserve image features. These preprocessed images undergo semantic segmentation to isolate specific parts of an image, followed by feature extraction using an Improved Gray Level Co-occurrence Matrix (I-GLCM) to reveal fine patterns and textures in images. These features serve as input into the classification U-Net model integrated with GRU networks to improve the model performance. Finally, the classification result is expanded, and XAI is used for clear visual explanations of the model's predictions. The proposed Patho-Net model, which uses the 100X BreakHis dataset, achieves an accuracy of 98.90% in the classification of breast cancer.

Indexed as

breast cancerdeep learninggated recurrent unitHistopathology imagesU-Net and classification

Identifiers

PMID40084355
PMCPMC11897615

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.